<DOC>
	<DOCNO>NCT03020979</DOCNO>
	<brief_summary>Malignant ascites severe complication many type human cancer . Animal clinical analysis show angiogenesis play critical role formation malignant ascites . Therefore , drug apatinib target angiogenesis may control development malignant ascites . The study evaluate efficacy safety apatinib patient refractory malignant ascites .</brief_summary>
	<brief_title>A Clinical Trial With Apatinib Subjects With Refractory Malignant Ascites</brief_title>
	<detailed_description>The study investigate efficacy safety apatinib patient refractory malignant ascites . Patients performance status 0 1 assign 850mg group patient performance status 2 assign 500mg group continually disease progression intolerable toxicity patient withdrawal consent , sample size 120 individual .</detailed_description>
	<mesh_term>Ascites</mesh_term>
	<criteria>Persistent symptomatic ascites positive cytology secondary histologically confirm tumor type amenable cytoreductive surgery additional chemotherapy Patients may enroll study irrespective previous therapy include diuretic , surgery , chemotherapy , immunotherapy radiation therapy Must receive minimum two paracentesis procedure trial diuretic therapy within 60 day study entry Age Restrictions : 1875 year Life Expectancy : 12 week ECOG Performance Status : 02 Able willing provide inform consent comply study and/or followup procedure Normal organ marrow function define : Leukocytes &gt; /= 3,000/mcL ; Absolute neutrophil count &gt; /= 1,500/mcL ; Platelets &gt; /= 100,000/mcL ; Total bilirubin within normal institutional limit ; AST ( SGOT ) /ALT ( SGPT ) &lt; /= 2.5 X institutional upper limit normal ( ULN ) ; Creatinine within normal institutional limit OR Creatinine clearance &gt; /+ 60 mL/min patient creatinine level institutional normal ; Serum Potassium within normal institutional limit ; Serum Sodium within normal institutional limit Patients receive antiangiogenic agent part treatment malignancy within 60 day prior study entry Current , recent ( within 30 day first infusion study ) plan administration chemotherapy ( include route administration ) , immunotherapy , biologic therapy , radiation therapy antiangiogenic therapy ( e.g. , bevacizumab , tyrosine kinase inhibitor ) Current , recent ( within 30 day first infusion study ) , plan participation experimental drug study Pregnant woman ; A serum pregnancy test give female childbearing potential prior study enrollment participant must agree use adequate contraception ( barrier hormonal method ) prior study entry duration study participation . Uncontrolled hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg History hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction , unstable angina , stroke transient ischemic attack within 6 month prior study entry Known CNS disease , except treat brain metastasis . Significant vascular disease ( e.g. , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior study entry History hemoptysis ( &gt; /= 1/2 teaspoon bright red blood per episode ) within 1 month prior study entry Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study entry anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device paracentesis/thoracentesis , within 7 day prior study entry History abdominal fistula gastrointestinal perforation within 6 month prior study entry Any bowel obstruction fully recover despite medical surgical intervention prior study entry Evidence bowel wall thicken outside site know primary malignancy baseline radiograph Serious , nonhealing wound , active ulcer , untreated bone fracture Proteinuria demonstrate Urine Protein/Creatinine ration &gt; /= 1.0 screen Known hypersensitivity component apatinib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>